

Publications Generated per John C Martin Foundation Support of UCSD Gastroenterology & Hepatology

Gawrieh S, Vilar-Gomez E, Woreta TA, et al. **Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.** *Alimentary Pharmacology & Therapeutics* 2024;59:666-679. <https://doi.org/10.1111/apt.17849>

Bridi L, Agrawal S, Tesfai K, et al. **The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.** *Alimentary Pharmacology & Therapeutics* 2024;60:369-377. <https://doi.org/10.1111/apt.18099>

Clark VC, Strange C, Strnad P, et al. **Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)** *Gastroenterology* 2024;167:1008-1018. DOI: [10.1053/j.gastro.2024.06.028](https://doi.org/10.1053/j.gastro.2024.06.028)

Díaz LA, Lazarus JV, Fuentes-López E, et al. **Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria.** *Commun Med* 2024;4:1-11. <https://doi.org/10.1038/s43856-024-00649-x>

Lim WH, Tay P, Ng CH, et al. **Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis** *Alimentary Pharmacology & Therapeutics* 2024;59:730-741. <https://doi.org/10.1111/apt.17888>

Loomba R, Amangurbanova M, Bettencourt R, et al. **MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH.** *Gut* 2024;73:1343-1349. <https://doi.org/10.1136/gutjnl-2023-331401>